MiNK Therapeutics, Inc.

EDGAR

Market value

$49.82M

5,133,645 shares as of 2026-11-06, at $9.705 a share (INKT, IEX close on 2026-11-12) Primary-source evidence

28 filing records in this dataset, filed from 2021-09-14 to 2026-11-12. Reported financial figures are available; chart coverage varies by period.

Watchlist

Holdings and insider activity

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.

Window: transactions dated on or after 2025-11-21.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
9 transactions, 10,438 shares
Sum of shares × price per share: 119,884.19

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

  • 2026-10-12 Buell Jennifer S 6,938 10.56
  • 2026-10-11 Buell Jennifer M 23,191 —
  • 2026-10-11 Buell Jennifer M 23,191 0.00
  • 2026-09-01 Behner Peter A 1,485 10.95
  • 2026-09-01 Ryan Barbara A 1,622 10.95

Institutional holders (Form 13F)

  • VANGUARD CAPITAL MANAGEMENT LLC 68,452 SH
  • DNB ASSET MANAGEMENT AS 43,960 SH
  • GEODE CAPITAL MANAGEMENT, LLC 18,759 SH
  • Longbow Finance SA 16,667 SH
  • VANGUARD FIDUCIARY TRUST CO 13,164 SH

Trades by members of Congress

See all insider transactions

Latest quarter

Revenue

200 thousand USD

2026 Q3 · USD

Exact inputs and evidence

Operating margin

-1,318.5%

2026 Q3 · %

Exact inputs and evidence
  • Operating Income: -2637000 USD Source
  • Revenue: 200000 USD Source

Operating cash flow

-1.28 million USD

2026 Q3 · USD

Exact inputs and evidence
  • Operating Cash Flow: -5091036 USD Source
  • Operating Cash Flow: -3815409 USD Source
Cash and cash equivalents
7.5 million USD Source
Exact value

7500000 USD

Long-term debt including current maturities
Not available
Shares outstanding
5.1 million shares Source
Exact value

5103083 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Operating cash flow

-7.16 million USD

2025-10-01 – 2026-09-30

Exact inputs and evidence
  • Operating cash flow: -5925168 USD · 2025-01-01 – 2025-12-31 Source
  • Operating cash flow: -3851442 USD · 2025-01-01 – 2025-09-30 Source
  • Operating cash flow: -1732597 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -3815409 USD · 2026-01-01 – 2026-06-30 Source
  • Operating cash flow: -1732597 USD · 2026-01-01 – 2026-03-31 Source
  • Operating cash flow: -5091036 USD · 2026-01-01 – 2026-09-30 Source
  • Operating cash flow: -3815409 USD · 2026-01-01 – 2026-06-30 Source

Capital expenditure

73.6 thousand USD

2023-01-01 – 2023-12-31

Exact inputs and evidence
  • Capital expenditure: 13500 USD · 2023-01-01 – 2023-03-31 Source
  • Capital expenditure: 50518 USD · 2023-01-01 – 2023-06-30 Source
  • Capital expenditure: 13500 USD · 2023-01-01 – 2023-03-31 Source
  • Capital expenditure: 73561 USD · 2023-01-01 – 2023-09-30 Source
  • Capital expenditure: 50518 USD · 2023-01-01 – 2023-06-30 Source
  • Capital expenditure: 73561 USD · 2023-01-01 – 2023-12-31 Source
  • Capital expenditure: 73561 USD · 2023-01-01 – 2023-09-30 Source

Company performance

Up to ten complete financial years · consolidated figures

Latest filing vintage with reviewed corrections applied; these values remain separate from issuer-reported figures. Annual charts exclude incomplete years.

Latest filing recorded: 2026-11-12.

Financial data available through: 2025-12-31.

Coverage by financial measure
  • revenue: No compatible figures in this window
  • Operating income: 6 of 11 periods available· newest 2025-12-31
  • Net income: 6 of 11 periods available· newest 2025-12-31
  • Operating cash flow: 6 of 11 periods available· newest 2025-12-31
  • Capital expenditure: 4 of 11 periods available· newest 2023-12-31
  • Total assets: 6 of 11 periods available· newest 2025-12-31
  • liabilities: No compatible figures in this window
  • Current assets: 6 of 11 periods available· newest 2025-12-31
  • Current liabilities: 6 of 11 periods available· newest 2025-12-31
  • Cash and cash equivalents: 5 of 11 periods available· newest 2025-12-31
  • long term debt: No compatible figures in this window
  • Shares outstanding: 5 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

  • Net income

    −USD 1.71 million

    Prior period

    −USD 10.79 million

    –

    Current period

    −USD 12.49 million

    –

    Exact inputs and evidence

    -12494000 − -10785000 = -1709000 USD

    -10785000 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -12494000 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

  • Operating cash flow

    +USD 3.63 million

    Prior period

    −USD 9.56 million

    –

    Current period

    −USD 5.93 million

    –

    Exact inputs and evidence

    -5925168 − -9555476 = 3630308 USD

    -9555476 USD · 2024-01-01 – 2024-12-31

    Inspect prior input Prior source

    -5925168 USD · 2025-01-01 – 2025-12-31

    Inspect current input Current source
    Share or cite

    The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

Revenue is not reported for this company, so its costs cannot be shown as a share of it.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Not enough comparable data to show this history.
Values and sources
Revenue values and source evidence
PeriodSeriesValueSource evidence

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.
Values and sources
Revenue growth values and source evidence
PeriodSeriesValueSource evidence

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.
  • Operating margin
  • Net margin
  • Free cash flow margin
Values and sources
Profit margins values and source evidence
PeriodSeriesValueSource evidence

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.
Values and sources
Operating cash flow values and source evidence
PeriodSeriesValueSource evidence

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.
Values and sources
Free cash flow values and source evidence
PeriodSeriesValue(USD)Source evidence

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.
Values and sources
Liabilities to assets values and source evidence
PeriodSeriesValueSource evidence

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.
Values and sources
Current assets to current liabilities values and source evidence
PeriodSeriesValueSource evidence

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
PeriodNet incomeOperating cash flowCapital expenditureFree cash flow
2020 2020-01-01 – 2020-12-31
−USD 16.24 million
Exact value

Exact value: -16238898 USD

2020-01-01 – 2020-12-31: -16238898 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 8.34 million
Exact value

Exact value: -8337770 USD

2020-01-01 – 2020-12-31: -8337770 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 95,212
Exact value

Exact value: 95212 USD

2020-01-01 – 2020-12-31: 95212 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 8.43 million
Calculation and evidence

-8337770 − 95212 USD

Exact free cash flow: -8432982 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2021 2021-01-01 – 2021-12-31
−USD 30.21 million
Exact value

Exact value: -30212770 USD

2021-01-01 – 2021-12-31: -30212770 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 12.83 million
Exact value

Exact value: -12827117 USD

2021-01-01 – 2021-12-31: -12827117 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 248,983
Exact value

Exact value: 248983 USD

2021-01-01 – 2021-12-31: 248983 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 13.08 million
Calculation and evidence

-12827117 − 248983 USD

Exact free cash flow: -13076100 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2022 2022-01-01 – 2022-12-31
−USD 27.99 million
Exact value

Exact value: -27991212 USD

2022-01-01 – 2022-12-31: -27991212 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 18.87 million
Exact value

Exact value: -18866843 USD

2022-01-01 – 2022-12-31: -18866843 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 250,046
Exact value

Exact value: 250046 USD

2022-01-01 – 2022-12-31: 250046 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 19.12 million
Calculation and evidence

-18866843 − 250046 USD

Exact free cash flow: -19116889 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2023 2023-01-01 – 2023-12-31
−USD 22.46 million
Exact value

Exact value: -22458000 USD

2023-01-01 – 2023-12-31: -22458000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 15.76 million
Exact value

Exact value: -15762512 USD

2023-01-01 – 2023-12-31: -15762512 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

USD 73,561
Exact value

Exact value: 73561 USD

2023-01-01 – 2023-12-31: 73561 USD Inspect Capital Expenditure Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 15.84 million
Calculation and evidence

-15762512 − 73561 USD

Exact free cash flow: -15836073 USD

Share or cite

The citation records this snapshot. The page link may show a newer release later.

2024 2024-01-01 – 2024-12-31
−USD 10.79 million
Exact value

Exact value: -10785000 USD

2024-01-01 – 2024-12-31: -10785000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 9.56 million
Exact value

Exact value: -9555476 USD

2024-01-01 – 2024-12-31: -9555476 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

2025 2025-01-01 – 2025-12-31
−USD 12.49 million
Exact value

Exact value: -12494000 USD

2025-01-01 – 2025-12-31: -12494000 USD Inspect Net Income Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

−USD 5.93 million
Exact value

Exact value: -5925168 USD

2025-01-01 – 2025-12-31: -5925168 USD Inspect Operating Cash Flow Open source
Share or cite

The citation records this snapshot. The page link may show a newer release later.

Unavailable Not reported for this period.
Unavailable

Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

28 filings · 1,144 latest values · 1,144 originally reported values

Dataset published . Source filing dates and reporting periods are shown separately.

Identifiers: 0001840229, 1840229, INKT, edgar:1840229

Also known as AgenTus Therapeutics, Inc., MiNK Therapeutics, Inc.